Produced by recombinant DNA technology using E. coli
Pharmaceutical Form
Sterile lyophilized powder / solution for injection
Description
Structurally and biologically identical to endogenous human growth hormone
Mechanism of Action
Stimulates linear growth, protein synthesis, bone growth, and metabolic regulation
Therapeutic Indications
Growth hormone deficiency in children Turner syndrome Chronic renal insufficiency–associated growth failure Small for Gestational Age (SGA) without catch-up growth Prader–Willi syndrome Growth hormone deficiency in adults
Route of Administration
Subcutaneous injection
Dosage
Individualized as per indication and patient response
Storage Conditions
Store at 2°C–8°C; do not freeze; protect from light
Shelf Life
24–36 months (as per stability data)
Packaging
Vials / cartridges (export pack customizable)
Regulatory Status
Prescription drug; WHO-GMP compliant; CTD / ACTD dossier available
Inswan® – Recombinant Human Insulin
Parameter
Details
Product Name
Inswan®
Active Ingredient
Human Insulin (rDNA origin)
Pharmaceutical Form
Sterile solution / suspension for injection
Description
Recombinant human insulin identical to endogenous insulin